April 26, 2025 — An enduring and versatile mainstay of therapy for type 2 diabetes, metformin never ceases to earn our respect. On Thursday in JAMA, researchers showed this humble drug delivers improvements in knee pain for persons with overweight or obesity and osteoarthritis. In this six-month study of 107 persons randomized to either placebo or up to 2,000 […]
January 1, 2025 — Thankfully, 2024 is behind us now and we have a blank slate for a whole new year ahead of us. But what can we expect? Well, proverbial (probably Danish) wisdom tells us “prediction is difficult, especially if it’s about the future.” Nonetheless, here are our top five predictions about what we will see in 2025 […]
November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
November 2, 2024 — As we travel to San Antonio for ObesityWeek 2024 (OW2024) one of the principal threads we want to explore is the expanding scope of GLP-1 therapy benefits. The narrative is a moving target. We won’t have the abstracts in hand for another day. But news this week makes it clear that we have barely gotten […]
